UBS Group Upgrades Fresenius Medical Care AG & Co. (FMS) to “Neutral”

UBS Group upgraded shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a sell rating to a neutral rating in a research note released on Thursday, 99wallstreet.com reports.

Several other brokerages have also recently issued reports on FMS. Nord/LB reiterated a buy rating on shares of Fresenius Medical Care AG & Co. in a research report on Tuesday, January 2nd. SunTrust Banks set a $62.00 price target on Fresenius Medical Care AG & Co. and gave the company a buy rating in a research report on Thursday, December 21st. Morgan Stanley cut Fresenius Medical Care AG & Co. from an overweight rating to an equal weight rating in a research report on Monday, December 11th. DZ Bank reiterated a buy rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, December 18th. Finally, Zacks Investment Research cut Fresenius Medical Care AG & Co. from a hold rating to a sell rating in a research report on Tuesday, October 3rd. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $55.67.

Shares of Fresenius Medical Care AG & Co. (NYSE FMS) traded up $0.29 during mid-day trading on Thursday, hitting $54.59. The stock had a trading volume of 130,587 shares, compared to its average volume of 150,420. Fresenius Medical Care AG & Co. has a one year low of $39.46 and a one year high of $54.81. The firm has a market cap of $33,345.09, a PE ratio of 24.48, a PEG ratio of 2.26 and a beta of 0.45. The company has a current ratio of 1.22, a quick ratio of 0.98 and a debt-to-equity ratio of 0.55.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Harding Loevner LP boosted its stake in shares of Fresenius Medical Care AG & Co. by 4,271.1% during the 3rd quarter. Harding Loevner LP now owns 163,837,558 shares of the company’s stock worth $31,245,000 after acquiring an additional 160,089,385 shares in the last quarter. Cambiar Investors LLC boosted its stake in shares of Fresenius Medical Care AG & Co. by 3.8% during the 3rd quarter. Cambiar Investors LLC now owns 2,695,714 shares of the company’s stock worth $131,793,000 after acquiring an additional 99,234 shares in the last quarter. Royal Bank of Canada boosted its stake in shares of Fresenius Medical Care AG & Co. by 6.4% during the 2nd quarter. Royal Bank of Canada now owns 501,694 shares of the company’s stock worth $24,248,000 after acquiring an additional 30,119 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Fresenius Medical Care AG & Co. by 8.9% during the 3rd quarter. Parametric Portfolio Associates LLC now owns 431,183 shares of the company’s stock worth $21,081,000 after acquiring an additional 35,064 shares in the last quarter. Finally, Jarislowsky Fraser Ltd boosted its stake in shares of Fresenius Medical Care AG & Co. by 1.2% during the 3rd quarter. Jarislowsky Fraser Ltd now owns 294,871 shares of the company’s stock worth $14,416,000 after acquiring an additional 3,556 shares in the last quarter. 3.03% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “UBS Group Upgrades Fresenius Medical Care AG & Co. (FMS) to “Neutral”” was originally published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.com-unik.info/2018/01/08/ubs-group-upgrades-fresenius-medical-care-ag-co-fms-to-neutral.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

Analyst Recommendations for Fresenius Medical Care AG & Co. (NYSE:FMS)

What are top analysts saying about Fresenius Medical Care AG & Co.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fresenius Medical Care AG & Co. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit